ArticleScientific reports2025
Hemocompatible gelatin-glycidyl methacrylate/graphene oxide composite hydrogels for vascular catheter applications.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Siloxane-Reinforced GelMA/Methacrylated Chitosan Hydrogels for DLP Printing.Gels (Basel, Switzerland) · 2026Article
- Article
- Autofluorescence lifetime of gelatin-methacrylate hydrogels is sensitive to changes in crosslinking and post-gelation pH.Frontiers in bioengineering and biotechnology · 2026Article
- Smart Hydrogels in Wearable Electronics for Wound Treatments.Small (Weinheim an der Bergstrasse, Germany) · 2025Review
- Biocompatible ZnO nanoflower-infused chitosan/alginate/PVA composite for accelerated skin regeneration.Journal of materials science. Materials in medicine · 2025Article
- Development of an Artificial Neural Network-Based Tool for Predicting Failures in Composite Laminate Structures.Biomimetics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of biocompatible and hemocompatible materials is crucial for various biomedical applications. In this study, gelatin (Gel) was modified using glycidyl methacrylate (GMA) to create a photo-curable macromer (Gel-GMA), facilitating subsequent crosslinking via UV radiation. Additionally, a composite was prepared by incorporating graphene oxide (GO) into the modified gelatin matrix (Gel-GMA/GO). Structural and morphological analyses revealed macroporous or interconnected structures in the hydrogels and composites, resulting in high swelling capacities (> 1050%). Hemolysis testing demonstrated minimal hemolytic activity for both Gel-GMA and Gel-GMA/GO hydrogels, confirming their excellent hemocompatibility (0.54 and 0.50% respectively). Prothrombin time (PT) tests indicated negligible differences compared to normal blood, suggesting low thrombogenicity. The incorporation of GO reduced the PT to 12.9s. Furthermore, in vitro degradation studies under simulated blood conditions revealed moderate degradation rates) for Gel-GMA and Gel-GMA/GO hydrogels (37 and 18%, respectively) after 30 days. Viability assays on MRC-5 cells exposed to composite extracts up to 500 µg/ml showed consistent cell viability (more than 91.7%), with a slight reduction at higher concentrations. These findings underscore the potential of the hydrogels for applications such as vascular catheters, highlighting their biocompatibility, hemocompatibility, and controlled degradability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.